Supernus Pharmaceuticals Inc (SUPN)

NASDAQ
36.23
-0.04(-0.11%)
After Hours
36.23
0.00(0.00%)
- Real-time Data
  • Volume:
    549,179
  • Day's Range:
    36.06 - 36.74
  • 52 wk Range:
    24.95 - 42.09

SUPN Comments

What is your sentiment on Supernus?
or
Market is currently closed. Voting is open during market hours.

All Comments

(5)
  • good fundamentals, discount price, solid company. Nice price to add @ 25,20?
    0
    • Josef Kurzmannwhat do you find it was not good in the last report?
      0
    • declining earnings and revenues compared to the prior quarter.
      0
    • i know if the earnings and revenues decline for 1 quarter it isn't a big thing but what will happen if they decline for 2 or 3 quarters, we would possible see $15
      0
  • i sold a couple of days ago, seems like the real market crash is finally coming. I'll re-visit SUPN in a couple of months and decide if the share price fell deep enough.
    3
    • yesterday i sent this stock as an "tip" to some stock advisors and hedge funds (only about 5 combined). the price rose 4.38% and today it is up 3.39% in the pre-market. i will tell more fund managers about this stock and then the price should jump really quick.
      3
      • That moment when Josef thinks he is moving markets 😂
        1
    • one more time:I don't have the knowledge to make an educated guess if the FDA will or will not approve the new ADHD treatment and i am pretty sure you don't have the knowledge and insight eigther.What i know if that SUPN had a great balance sheet, is growing it's revenues 30% per year/earnings 40% per year both since 2016. I also know that their P/E ratio is at 12.5. so i can tell you, even if the new drug doesn't get approved the stock should be at around $90 per share (4.5 billion market cap). Right now it is at $30. If the new drug gets approved it should easily be at $100+ by the end of next year (December 2022) that is a 200%+ return in 23 months.
      1
      • BBRW
        1
    • supernus has a great risk/reward ratio. since 2016 earnings and revenues more than doubled yet the stock price is down 50% ($30 as I'm writing) . revenues and earnings are growing very fast (30%/40%p.a.) and this all makes it very likely that this stock quadrouples over the next 3-5 years.
      1
      • and i didn't even factor in that they have a new revolutionary treatment for ADHD in trial 3 that could be approved by the FDA (then the stock would be worth even more).
        1